Deliver Biosciences offers a customizable nanoparticle platform for targeted in vivo delivery of genetic payloads like DNA and mRNA. This technology enables direct cell reprogramming and the development of scalable, affordable cell and gene therapies, initially for cancer immunotherapies.
Funding
Funding not disclosed
Founders
Product
Problem
Developing effective and targeted cell and gene therapies faces challenges in delivering therapeutic payloads precisely to specific cells within the body. Current methods can be complex, require specialized manufacturing, and may lead to off-target effects, limiting patient access and therapeutic efficacy.
Solution
Deliver Biosciences has developed a customizable nanoparticle delivery platform designed for efficient and targeted transport of diverse payloads, including DNA and mRNA, to specific cell types in vivo. This technology aims to overcome the limitations of existing cell and gene therapies by enabling direct in vivo cell reprogramming. The platform is engineered to avoid accumulation in off-target organs and is designed for ease of loading and mass production. This approach facilitates the development of scalable, affordable, and potent cell and gene therapies, initially focusing on cancer immunotherapies and with potential applications in autoimmune, neurodegenerative, and cardiovascular diseases.
Target Audience
The primary customers are biopharmaceutical companies and research institutions developing advanced cell and gene therapies, particularly those focused on oncology, autoimmune diseases, neurodegenerative disorders, and cardiovascular conditions.
Features
- Customizable nanoparticle vectors for targeted delivery of genetic material (DNA, mRNA) to specific cell populations.
- In vivo cell reprogramming capabilities, enabling gene editing tools like CRISPR.
- Designed to minimize accumulation in off-target organs, such as the liver.
- Facilitates the development of CAR-T cell therapies by delivering chimeric antigen receptor genes.
- Streamlined administration and manufacturing processes compared to traditional ex vivo cell therapy methods.
- Programmable targeting domains allow for modification of various cell types, including stem cells, neurons, and cardiomyocytes.
- Platform technology adaptable for a broad range of therapeutic indications beyond oncology.